摘要
目的 探讨阿托伐他汀对慢性阻塞性肺疾病（COPD）合并肺动脉高压（PH）患者慢性炎症反应的影响及其安全性.方法 选择COPD合并PH患者78例,随机分为阿托伐他汀组和常规组,两组各39例.常规组采用常规治疗措施治疗,阿托伐他汀组在常规组基础上加用阿托伐他汀.比较两组患者治疗前、治疗后3个月时炎性因子、一氧化氮（NO）、内皮素-1（ET-1）、肺动脉平均压（PAPm）、肺动脉收缩压（PAPs）及肺功能指标变化情况.结果 两组患者治疗后白细胞介素（IL）-6、肿瘤坏死因子（TNF）-α、C反应蛋白（CRP）、ET-1、肺动脉平均压（PAPm）、肺动脉收缩压（PAPs）水平均较治疗前明显降低（P＜0.05）,但阿托伐他汀组降低程度更明显（P ＜0.05）;NO、FEV1％、FVC较治疗前明显升高（P＜0.05）,而阿托伐他汀组升高程度更明显（P＜0.05）.阿托伐他汀组服药期间无明显不良反应发生.结论 阿托伐他汀可降低COPD合并PH患者的各种细胞炎性因子,减轻炎症反应,调节NO与ET-1的平衡,降低PH,同时减少肺损伤,改善肺功能,疗效安全可靠,可作为治疗COPD合并PH的有效药物.
Objective To investigate the effect of chronic inflammationin of patients with chronic obstructive pulmonary disease（COPD） complicated with pulmonary arterial hypertension（PH） by atorvas- tatin and its safety. Methods 78 patients with COPD complicated with PH were selected,they were ran- domly divided into atorvastatin group and routine group,there were 39 cases in each group. Routine group were treated with conventional treatment mothod, atorvastatin group were treated with atorvastatin on basis of routine group. The change of inflammatory cytokines, nitric oxide （ NO ）, endothelin 1 （ ET-1 ）, mean pulmonary arterial pressure （PAPm）, systolic pulmonary artery pressure （PAPs） and lung function were eompared between two groups. Results The IL-6,TNF-α, CRP, ET-1, PAPm, PAPs levels after treatment were significantly lower than those before treatment in each group （ P 〈 0.05 ） , but those in atorvastatin group decreased more obviously （ P 〈 0.05 ） ; the NO, FEV1% , FVC after treatment were significantly higher than those before treatment in each group（ P 〈 0.05 ） ,but those in atorvastatin group raised more obviously（ P 〈 0.05 ）. There was no obvious adverse reactions occur in atorvastatin group. Conclusion Atorvastatin can reduce inflammatory cytokines in patients with COPD complicated with PH, reduce inflammation, regulate NO and ET-1 balance, reduce PH, at the same time can reduce lung injury,improve lung function. It is safe and its curative effect is reliable,it can be used as a effective methods in treating COPD with PH.
出处
《临床内科杂志》
CAS
2015年第1期26-28,共3页
Journal of Clinical Internal Medicine
关键词
阿托伐他汀
慢性阻塞性肺疾病
肺动脉高压
慢性炎症反应
Atorvastatin
Chronic obstructive pulmonary disease
Pulmonary artery hyper-tension
Chronicinflammation
